Watson for Oncology
A tumor board changed their decision due to Watson for Oncology in 13.6% of the cases.
Watson for Genomics
Identified additional actionable mutations in 32% of the cases that were not found by multidisciplinary tumor board.
Watson for Clinical Trial Matching
Enrollment to Mayo's systemic therapy clinical trials for breast cancer increased on average by 84%.